Wold Erik D, Axup Jun Y, Felding Brunhilde H, Smider Vaughn V
Department of Chemistry and the Skaggs Institute for Chemical Biology, ‡Department of Chemical Physiology, and §Department of Cell and Molecular Biology, The Scripps Research Institute , 10550 North Torrey Pines Road, La Jolla, California 92037, United States.
Bioconjug Chem. 2015 Dec 16;26(12):2311-4. doi: 10.1021/acs.bioconjchem.5b00530. Epub 2015 Nov 13.
Antibody therapeutics are a promising drug class due to their high specificity and favorable pharmacokinetics. While there are many methods for the development of antibodies specific to disease associated antigens, selecting antibodies against functional epitopes with high specificity and affinity can be difficult for certain epitopes. We describe a generalizable method for synthesizing antibody mimetics by site specifically conjugating small molecules (with high affinity and specificity to disease associated antigens) to an Fc fragment to develop drugs with the benefits of an antibody. As a proof of concept, an E269pAcPhe Fc antibody Fc fragment was produced and subsequently site-specifically labeled with a linker-modified folic acid compound to generate an Fc-folic acid antibody-mimetic. This was chosen as the model system because the high-affinity folate receptor FR-α is highly expressed in a number of cancer types including breast and ovarian cancer. The specificity of the Fc-folic acid conjugate was assessed via flowcytometry with the folate-receptor positive breast cancer cell line MDA-MB-231 by measuring Fc-folic acid binding in both the absence and presence of an excess of folic acid. Fc-small molecule conjugates could be developed into a unique class of antibody-like therapeutics.
抗体疗法因其高特异性和良好的药代动力学而成为一类有前景的药物。虽然有许多方法可用于开发针对疾病相关抗原的特异性抗体,但对于某些表位而言,选择具有高特异性和亲和力的针对功能性表位的抗体可能具有挑战性。我们描述了一种通用方法,通过将小分子(对疾病相关抗原具有高亲和力和特异性)位点特异性缀合至Fc片段来合成抗体模拟物,从而开发出具有抗体优点的药物。作为概念验证,制备了E269pAcPhe Fc抗体的Fc片段,随后用连接子修饰的叶酸化合物进行位点特异性标记,以生成Fc-叶酸抗体模拟物。选择该模型系统是因为高亲和力叶酸受体FR-α在包括乳腺癌和卵巢癌在内的多种癌症类型中高表达。通过流式细胞术,使用叶酸受体阳性的乳腺癌细胞系MDA-MB-231,在不存在和存在过量叶酸的情况下测量Fc-叶酸结合,评估Fc-叶酸缀合物的特异性。Fc-小分子缀合物可被开发成一类独特的类抗体疗法。